Chromosome analysis of transformed cells demonstrated a high rate of end-to-end fusions in transformed settings, the absence of telomerase function would appear to be having the expected negative effect on cellucells without telomerase activity and a marked reduction in such defects in cells with restored telomerase lar life span and viability. In the developing cancer cells of these mice, however, such checkpoint functions function. The authors propose that the efficiency of transformation of cells carrying the Ink4A deletion was might have been mutationally eliminated early on, leading to a state in which chromosomal damage is tolerated negatively affected by the induction of checkpoint mechanisms, including those controlled by the p53 and actually drives the development of a tumor. If this conclusion is extrapolated to humans, then one imaggene, in response to the loss of telomeric sequences and the ensuing genomic damage. ines that the effect of treatment of human tumors with telomerase inhibitors might be highly context depenp53 Makes a Difference The accompanying paper by Chin et al. (1999) further dent. In tumors in which such checkpoints were intact, senescence or apoptosis might ensue after telomerase explores how p53 status modulates the effects of telomerase deficiency. Since loss of telomere function ininhibitor treatment (this would be good), whereas in tumors in which these pathways were already abrogated, duces extensive secondary DNA damage, a role for p53 in the mTR Ϫ/Ϫ phenotype is expected. Indeed, they find the antitelomerase treatment might promote tumor progression (this would be bad).
that absence of p53 function can rescue some of the cellular and organismal defects in the late generation Reduced Tumorigenesis in Ink4A/mTR Double Mutant Mice mTR mice, including apoptosis in spermatocytes and infertility in G6 males and females, allowing further In the most recent papers on the mTR null mouse, the effects of genetic context in the response to telomere breeding. Consistent with a role for p53 in the cellular response to telomere loss in late generation mTR Ϫ/Ϫ loss and the consequences for tumor formation are addressed directly. As in most things, context matters.
MEFs, the authors show, using a number of assays, that the p53 pathway is activated in these cells. As in other Two reports assessed the effects of combining the mTR mutation with each of two tumor-promoting mutations:
cases of induction of the p53 checkpoint (e.g., following gamma irradiation of cultured cells), the G6 mTR Ϫ/Ϫ ;p53 ϩ/ϩ a deletion in the Ink4A locus (which encodes the tumor suppressors p16
INK4A and p19
ARF
) and mutation of p53 MEFs showed reduced S phase fractions and more cells in the G1 and G2 phases of the cell cycle. Elimination (Chin et al., 1999; Greenberg et al., 1999) . In both cases, the tumor suppressor mutations were initially crossed of p53 function largely relieved these cell cycle blocks, and G6 mTR Ϫ/Ϫ ;p53 Ϫ/Ϫ MEFs were shown to be capable onto the mTR mutant background and then carried through successive generations in the absence of teloof active cell cycling. Thus, in developing male germ cells in vivo and in MEFs in culture, absence of p53 merase activity in order to bring the telomeres down to a reasonably short starting length. function changed the fate of telomere-deficient cells, from death to viability and from cell cycle arrest to proFor those looking to the mTR mutant mouse to reinforce the telomerase-cancer connection, the cross to gression. Precisely what p53 is responding to in these settings is not known, but the high frequency of chromothe Ink4A brought good news. Greenberg et al. (1999) reported that following a two-step, in vivo carcinogenesomal defects present in late generation telomerasedeficient cells makes it likely that activation of DNA sis protocol, late generation (G3-G5) animals with the damage signals is part of the process. In addition, it is the rate of cellular transformation is presumed to be possible that the very short telomeres lack sufficient high and probably not limiting, thus focusing attention TRF2, the telomeric capping protein required to supon later stages of tumorigenesis. Arguably, this situation press the activation of p53 by chromosome ends (Karlmore closely resembles events in the clinic, where treatseder et al., 1999). ment traditionally focuses on inhibiting the growth of However, absence of p53 was not able to fully rescue established tumors rather than on tumor initiation. As all effects of prolonged telomerase deficiency. In G8 such, these findings on the mTR knockout mouse bode mTR Ϫ/Ϫ ;p53 Ϫ/Ϫ male mice, histological defects and abwell for future telomerase therapy. Moreover, even if sence of germ cells were noted in testes, causing steriltelomerase inhibitors turn out to increase the mutation ity. Therefore, p53-independent mechanisms must exist rate in human cancers, they would have this feature in that can induce arrest and/or death when the loss of common with the majority of the current cancer therachromosomal sequences is even more extensive. Likepeutics, and the short-term advantages of the drugs wise, in experiments with human cells in culture, may still outweigh the minor risk of creating a more p53-independent cell death mechanisms have been aggressive tumor by inducing additional mutations. In suggested to account for the "crisis" phase that prethe end, we must await the development and testing of cedes the outgrowth of telomerase-positive immortaltelomerase inhibitors for use in human tumor cells. Only ized clones (Shay et al., 1993) . then will we know whether the mTR mutant mouse is Tumor development is facilitated by mutations that pointing with its paws up or its paws down. affect overall genomic stability. Given the high degree of chromosomal disarray caused by telomere erosion
